Attendees will gain insight into the Company’s drug development strategy, growing partnership network, and clinical trials VANCOUVER, BC, May 8, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on…


Previous articleClearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Next articleDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001